Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dove Medical warning letter rescinded by FDA due to agency filing error.

This article was originally published in The Gray Sheet

Executive Summary

DOVE MEDICAL WARNING LETTER ISSUED DUE TO FILING ERROR has been rescinded, FDA says in a Nov. 5 letter to the company. The Oct. 29 warning letter cited the firm for not filing an initial product report or annual reports for its OsteoAnalyzer. In the rescission letter, FDA acknowledges that it mistakenly issued the letter because it could not locate files.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT007029

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel